Cambridge Nutritional Science (CNSL)

Sector:

Health Care

Index:

FTSE AIM All-Share

3.60p
   
  • Change Today:
    -0.050p
  • 52 Week High: 4.35
  • 52 Week Low: 1.73
  • Currency: UK Pounds
  • Shares Issued: 237.95m
  • Volume: 455,064
  • Market Cap: £8.57m

Omega gets CE-marking for Covid-19 test, working on UK approval

By Josh White

Date: Thursday 03 Feb 2022

LONDON (ShareCast) - (Sharecast News) - Medical diagnostics specialist Omega has successfully CE-marked its 'Visitect' Covid-19 antigen test for self-test use, it announced on Thursday.
The AIM-traded firm said the test would provide consumers with an accurate rapid test for the detection of the nucleoprotein of the SARS-CoV-2 virus in nasal swabs only.

It said the test had "excellent" performance characteristics following independent multi-centre validations, with sensitivity of 93.2% based on 103 samples with cycle threshold (Ct) values of less than 25, and 97.8% specificity, based on 230 RT-qPCR negative samples.

The company said it was in discussion with commercial partners over how best to service the European market and other territories that recognise the CE-mark.

Omega said its commercial offering would be via business partners and distributors, and not through a direct-to-consumer strategy.

The CE-mark certificate is conditional on the submission of additional data and follow-up reports by 31 March, which Omega said it was working with its external study centres to ensure is met.

It a;sp remained in the review process under the UK's Coronavirus Test Device Approvals (CTDA) regulations, which were introduced in November.

Further field study data was recently requested, and Omega said it was seeking that information from external parties, but warned it might not be available before the current extended deadline for submission on 10 February.

"We are delighted to have reached this milestone, achieving CE-mark for our Visitect Covid-19 antigen test for the home-use market," said chief executive officer Jag Grewal.

"It is frustrating that our test is still awaiting approval under CTDA regulations for sale of the professional-use test in the UK."

Grewal said the company was looking to start the process of filing for approval to sell its home-use product in the UK.

"In the meantime, we look forward to working with prospective partners to determine the best route to market."

At 1522 GMT, shares in Omega Diagnostics Group were up 15.87% at 11.01p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

CNSL Market Data

Currency UK Pounds
Share Price 3.60p
Change Today -0.050p
% Change -1.37 %
52 Week High 4.35
52 Week Low 1.73
Volume 455,064
Shares Issued 237.95m
Market Cap £8.57m

CNSL Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
73.19% above the market average73.19% above the market average73.19% above the market average73.19% above the market average73.19% above the market average
83.78% above the sector average83.78% above the sector average83.78% above the sector average83.78% above the sector average83.78% above the sector average
Income Not Available
Growth Not Available

CNSL Dividends

No dividends found

Trades for 15-Jul-2024

Time Volume / Share Price
13:05 50,052 @ 3.51p
12:16 18,000 @ 3.51p
09:54 200,000 @ 3.57p
10:23 15,532 @ 3.51p
09:54 100,000 @ 3.56p

Top of Page